Login to Your Account

Will Firm 'AIM' for Public Listing?

Koronis Looking for Financing for HIV Viral Decay Accelerator

By Jennifer Boggs

Wednesday, March 16, 2011
Two months after a paper in PLoS One highlighted the potential of Koronis Pharmaceuticals Inc.'s HIV candidate KP-1461, the Seattle-based firm is working on the design of a Phase II study aimed at establishing dose and treatment duration for the drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription